Registered number
07980348
CLINICAL TRIAL SOLUTIONS LTD
Filleted Accounts
30 April 2024
CLINICAL TRIAL SOLUTIONS LTD
Registered number: 07980348
Balance Sheet
as at 30 April 2024
Notes 2024 2023
£ £
Current assets
Debtors 3 - 47
Cash at bank and in hand 144 359
144 406
Creditors: amounts falling due within one year 4 (7,810) (5,594)
Net current liabilities (7,666) (5,188)
Total assets less current liabilities (7,666) (5,188)
Creditors: amounts falling due after more than one year 5 (43,471) (44,229)
Net liabilities (51,137) (49,417)
Capital and reserves
Called up share capital 1 1
Profit and loss account (51,138) (49,418)
Shareholders' funds (51,137) (49,417)
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
M Sobti
Director
Approved by the board on 27 January 2025
CLINICAL TRIAL SOLUTIONS LTD
Notes to the Accounts
for the year ended 30 April 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Leased assets
A lease is classified as a finance lease if it transfers substantially all the risks and rewards incidental to ownership. All other leases are classified as operating leases. The rights of use and obligations under finance leases are initially recognised as assets and liabilities at amounts equal to the fair value of the leased assets or, if lower, the present value of the minimum lease payments. Minimum lease payments are apportioned between the finance charge and the reduction in the outstanding liability using the effective interest rate method. The finance charge is allocated to each period during the lease so as to produce a constant periodic rate of interest on the remaining balance of the liability. Leased assets are depreciated in accordance with the company's policy for tangible fixed assets. If there is no reasonable certainty that ownership will be obtained at the end of the lease term, the asset is depreciated over the lower of the lease term and its useful life. Operating lease payments are recognised as an expense on a straight line basis over the lease term.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
By a Deed dated 21/11/13 the company established a Remuneration Trust. During the accounting period the company contributed £1,000 to the Trust. No taxation liability arose to the company as a result of such transaction.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 1 1
3 Debtors 2024 2023
£ £
Other debtors - 47
4 Creditors: amounts falling due within one year 2024 2023
£ £
Taxation and social security costs - 953
Other creditors 7,810 4,641
7,810 5,594
5 Creditors: amounts falling due after one year 2024 2023
£ £
Bank loans 43,471 44,229
6 Other information
CLINICAL TRIAL SOLUTIONS LTD is a private company limited by shares and incorporated in England. Its registered office is:
29 Broadway
Bramhall
Stockport
SK7 3BT
CLINICAL TRIAL SOLUTIONS LTD 07980348 false 2023-05-01 2024-04-30 2024-04-30 VT Final Accounts July 2024 M Sobti No description of principal activity 07980348 2022-05-01 2023-04-30 07980348 core:WithinOneYear 2023-04-30 07980348 core:AfterOneYear 2023-04-30 07980348 core:ShareCapital 2023-04-30 07980348 core:RetainedEarningsAccumulatedLosses 2023-04-30 07980348 2023-05-01 2024-04-30 07980348 bus:PrivateLimitedCompanyLtd 2023-05-01 2024-04-30 07980348 bus:AuditExempt-NoAccountantsReport 2023-05-01 2024-04-30 07980348 bus:Director40 2023-05-01 2024-04-30 07980348 countries:England 2023-05-01 2024-04-30 07980348 bus:FRS102 2023-05-01 2024-04-30 07980348 bus:FilletedAccounts 2023-05-01 2024-04-30 07980348 2024-04-30 07980348 core:WithinOneYear 2024-04-30 07980348 core:AfterOneYear 2024-04-30 07980348 core:ShareCapital 2024-04-30 07980348 core:RetainedEarningsAccumulatedLosses 2024-04-30 07980348 2023-04-30 iso4217:GBP xbrli:pure